Post Time: 2025-02-18
Error: No content files found.#ozempic #wegovy relevant webpage #diabetic #yahoofinance Ozempic and Wegovy, made by Novo Nordisk (NVO), traditionally have been used to treat patients with type 2 diabetes, though they have gained notoriety as weight loss drugs. Research published by the New England Journal of Medicine shows that Semaglutide, the ingredient behind Ozempic and Wegovy, may also help those with type 1 diabetes. Yahoo Finance's Anjalee Khemlani reports on what these new findings mean for those living with diabetes, as well as what it means for Novo Nordisk, who may not be able to keep up with the such a good point demand for these popular drugs. CEO Lars Jorgensen told Reuters that "I think for the foreseeable future, we'll have a situation where demand will be larger than what we can supply." Subscribe to Yahoo Finance: About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more. To learn more about Yahoo Finance Plus please visit: Connect with Yahoo Finance: Get the latest news: Find Yahoo Finance on Facebook: Follow Yahoo Finance on mouse click the following web site Twitter: Follow Yahoo Finance on Instagram: Follow Yahoo Finance Premium on Twitter: